This Article Full Text Full Text (PDF) All Versions of this Article: 116/21/2427    most recent CIRCULATIONAHA.107.708768v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nettleship, J. E. Articles by Jones, R. D. Search for Related Content PubMed PubMed Citation Articles by Nettleship, J. E. Articles by Jones, R. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Hormone Replacement Therapy Hazardous Substances DB TESTOSTERONE Related Collections Lipids Mechanism of atherosclerosis/growth factors Animal models of human disease Risk Factors

(Circulation. 2007;116:2427-2434.)
© 2007 American Heart Association, Inc.

Vascular Medicine

Physiological Testosterone Replacement Therapy Attenuates Fatty Streak Formation and Improves High-Density Lipoprotein Cholesterol in the Tfm Mouse

An Effect That Is Independent of the Classic Androgen Receptor

Joanne E. Nettleship, BSc, PhD; T. Hugh Jones, BSc, MBChB, MD, FRCP; Kevin S. Channer, BSc, MBChB, MD, FRCP; Richard D. Jones, BSc, PhD

From the Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK (J.E.N., T.H.J., R.D.J.); Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK (T.H.J.); and Department of Cardiology, Royal Hallamshire Hospital, and Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK (K.S.C.).

Correspondence to Dr Joanne E Nettleship, Academic Unit of Diabetes, Endocrinology & Metabolism, University of Sheffield, Sheffield, UK. E-mail joannenettleship{at}hotmail.com

Received April 19, 2007; accepted August 7, 2007.

Background— Research supports a beneficial effect of physiological testosterone on cardiovascular disease. The mechanisms by which testosterone produces these effects have yet to be elucidated. The testicular feminized (Tfm) mouse exhibits a nonfunctional androgen receptor and low circulating testosterone concentrations. We used the Tfm mouse to determine whether testosterone modulates atheroma formation via its classic signaling pathway involving the nuclear androgen receptor, conversion to 17β-estradiol, or an alternative signaling pathway.

Methods and Results— Tfm mice (n=31) and XY littermates (n=8) were separated into 5 experimental groups. Each group received saline (Tfm, n=8; XY littermates, n=8), physiological testosterone alone (Tfm, n=8), physiological testosterone in conjunction with the estrogen receptor antagonist fulvestrant (Tfm, n=8), or physiological testosterone in conjunction with the aromatase inhibitor anastrazole (Tfm, n=7). All groups were fed a cholesterol-enriched diet for 28 weeks. Serial sections from the aortic root were examined for fatty streak formation. Blood was collected for measurement of total cholesterol, high-density lipoprotein cholesterol (HDLC), non-HDLC, testosterone, and 17β-estradiol. Physiological testosterone replacement significantly reduced fatty streak formation in Tfm mice compared with placebo-treated controls (0.37±0.07% versus 2.86±0.39%, respectively; P0.0001). HDLC concentrations also were significantly raised in Tfm mice receiving physiological testosterone replacement compared with those receiving placebo (2.81±0.30 versus 2.08±0.09 mmol/L, respectively; P=0.05). Cotreatment with either fulvestrant or anastrazole completely abolished the improvement in HDLC.

Conclusion— Physiological testosterone replacement inhibited fatty streak formation in the Tfm mouse, an effect that was independent of the androgen receptor. The observed increase in HDLC is consistent with conversion to 17β-estradiol.

---

 

CLINICAL PERSPECTIVE